CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 4, Randomized, Placebo-controlled, Cross-over Trial to Assess the Effect of 4-week Ertugliflozin (SGLT-2 Inhibitor) Therapy on Renal Oxygenation by BOLD-MRI and Renal Oxygen Consumption by PET Using ¹¹C-acetate in T2DM Without Kidney Disease and Healthy Controls.

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04027530
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:11.546331+00:00
Published At: 2023-05-01T00:00:00+00:00
Record Updated At: 2023-05-01
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Type 2 Diabetes Mellitus", "Diabetic Kidney Disease", "Diabetic Nephropathy", "Renal Hypoxia", "Renoprotection", "SGLT2 Inhibitor", "Ertugliflozin"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-05-01"
protocolSection.identificationModule.nctId: "NCT04027530"
protocolSection.identificationModule.officialTitle: "Phase 4, Randomized, Placebo-controlled, Cross-over Trial to Assess the Effect of 4-week Ertugliflozin (SGLT-2 Inhibitor) Therapy on Renal Oxygenation by BOLD-MRI and Renal Oxygen Consumption by PET Using \u00b9\u00b9C-acetate in T2DM Without Kidney Disease and Healthy Controls."
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE4"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.